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Drug resistance has been reported against all antimalarial drugs, and while parasites can evolve12
classical resistance mechanisms (e.g., efflux pumps), it is also possible that changes in life13
history traits could help parasites evade the effects of treatment. The life history of malaria14
parasites is governed by an intrinsic resource allocation problem: specialized stages are required15
for transmission, but producing these stages comes at the cost of producing fewer of the forms16
required for within-host survival. Drug treatment, by design, alters the probability of within-host17
survival, and so should alter the costs and benefits of investing in transmission. Here, we use a18
within-host model of malaria infection to predict optimal patterns of investment in transmission19
in the face of different drug treatment regimes and determine the extent to which alternative20
patterns of investment can buffer the fitness loss due to drugs. We show that over a range of21
drug doses, parasites are predicted to adopt “reproductive restraint” (investing more in asexual22
replication and less in transmission) to maximise fitness. By doing so, parasites recoup some23
of the fitness loss imposed by drugs, though as may be expected, increasing dose reduces the24
extent to which altered patterns of transmission investment can benefit parasites. We show25
that adaptation to drug treated infections could result in more virulent infections in untreated26
hosts. This work emphasises that in addition to classical resistance mechanisms, drug treatment27
generates selection for altered parasite life history. Understanding how any shifts in life history28
will alter the efficacy of drugs, as well as any limitations on such shifts, is important for evaluating29
and predicting the consequences of drug treatment.30




Malaria parasites (Plasmodium spp.) remain one of the most severe and common causes of34
human disease (White et al. 2014b). Though interventions against malaria parasites have35
seen significant successes over the last 30 years (WHO 2015a), resistance has evolved to every36
antimalarial drug in widespread use (Hyde 2005; White 2004; WHO 2015a). In many cases,37
this resistance has been attributed to “classical” resistance mechanisms (sensu Schneider et al.38
2012), including target site mutations or detoxification mechanisms (Hyde 2002, 2005). However,39
changes in parasite behaviour, metabolism, or life history, i.e., “non-classical” resistance mechanisms40
(Schneider et al. 2012), offer additional threats to drug efficacy.41
One potential mechanism for non-classical resistance is evolving traits that give rise to higher42
within-host parasite densities; this may offer protection against drugs by increasing the likelihood43
that some (genetically identical) parasites survive treatment (White 1998). Experimental rodent44
malaria infections confirm that more virulent parasite strains, with faster within-host replication,45
survive better in drug treated hosts (Schneider et al. 2012, 2008). But within-host densities are at46
least in part governed by a resource allocation trade-off in malaria and other sexually-reproducing47
parasites: achieving higher within-host densities comes at the cost of producing fewer specialised48
sexual stages (gametocytes) that are required for transmission (Carter et al. 2013; Pollitt et al.49
2011), since a parasite in a given infected host cell can follow only one of the two developmental50
routes. Transmission investment—by convention referred to as the conversion rate—varies51
plastically within artificial culture, increasing as conditions become more crowded (Bruce et al.52
1990). While conversion rate can change plastically in response to changing environmental53
conditions, data suggest that there is parasite genetic variation for patterns of conversion (Pollitt54
et al. 2011, Birget et al., submitted) and that this variation can be selected upon (reviewed in55
Bousema and Drakeley 2011). It is well known, for example, that serial passage and culture56
experiments, which by their nature select for faster within-host replication, result in reduced57
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transmission investment (Dearsly et al. 1990; Sinha et al. 2014, reviewed in Carter et al. 2013).58
Similarly, artificial selection for attenuation in a related parasite, Eimeria, resulted in indirect59
selection for earlier investment in transmission, which translated into a substantial reduction in60
total transmission potential (McDonald and Shirley 2009). Therefore, conversion rates represent61
an evolvable parasite trait essential to transmission, and the challenge is to explore if and how62
drug treatment might alter parasite strategies.63
Malaria parasites appear to vary transmission investment in ways thought to be adaptive64
(Carter et al. 2013), and theory is an essential check on intuition regarding the fitness consequences65
of different strategies (Greischar et al. 2016c). Models have shown that reducing transmission66
investment—though it might appear maladaptive (Taylor and Read 1997)—can dramatically67
enhance parasite fitness by increasing the parasite numbers available to produce gametocytes68
later on and by improving persistence in the face of immunity and competing strains (Greischar69
et al. 2016a,c; Koella and Antia 1995; McKenzie and Bossert 1998; Mideo and Day 2008).70
It remains challenging to show experimentally that these predicted patterns are adaptive, and71
actually improve parasite fitness in the face of environmental change, since techniques for forcing72
parasites to make alternative life history decisions are currently not available. However, the73
development of improved statistical methods now allows more accurate estimates of conversion74
rates in vivo (Greischar et al. 2016b), and theory is urgently needed to form clear expectations to75
compare with natural patterns. In contrast, conversion rates are comparatively easy to integrate76
into mathematical models by simply varying allocation to asexual growth and gametocyte77
production. Mathematical models demonstrate that changing allocation patterns can have78
significant impacts on parasite fitness (i.e., transmission potential) and can predict the optimal79
pattern in different environments (Greischar et al. 2016a, 2014; Koella and Antia 1995; McKenzie80
and Bossert 1998; Mideo and Day 2008). Understanding how selection imposed by drugs81
may alter transmission investment is critical, since any changes will have both clinical and82
epidemiological consequences.83
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Here, we predict the resource allocation patterns of malaria parasites that maximise fitness in84
drug treated hosts. We extend a previously published mechanistic model of within-host malaria85
infection (Greischar et al. 2016a, 2014) and use numerical optimisation techniques to determine86
optimal conversion rates, i.e., proportion of infected host cells that produce transmission stages.87
Into this framework, we incorporate a simple model of drug action that was parameterised for88
treatment of experimental rodent malaria infections with the anti-malarial drug pyrimethamine89
(Huijben et al. 2013). By holding constant the duration and timing of drug treatment, but90
varying dose, this heuristic model allows us to explore the predicted impact of treatment of91
variable efficacy – from small to large reductions in parasite load – on parasite life history92
evolution. We explore optimal investment in transmission stages, first, by assuming parasites93
are constrained to a constant conversion rate throughout infections and, second, by permitting94
parasites to employ time-varying conversion rates. Finally, we quantify the extent to which95
altering life history according to these optimal patterns can buffer against the effects of drugs96
and we evaluate the consequences for host health and onward transmission.97
2 Methods98
2.1 The model99
Following Greischar et al. (2016a, 2014), we use delay-differential equations to model the within-host100
dynamics of a malaria infection, which tracks uninfected red blood cells (R), infected red blood101
cells (I), extracellular malaria parasites (merozoites, M) and gametocytes (G). The change in102








− µR(t) − pR(t)M(t). (1)
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The first term represents production of new RBCs by the host. Erythropoiesis is assumed to be104
a logistic function of current RBC density, where λ is the maximum realized rate of replenishing105
depleted RBCs and K determines the homeostatic equilibrium. We assume that only uninfected106
RBCs count towards the homeostatic equilibrium since malaria parasites consume large amounts107
of haemoglobin during their development (e.g., Lew 2003) and compromise the ability of infected108
RBCs to carry oxygen (Schmidt et al. 1994). We have found that including infected RBCs in this109
term makes little qualitative difference. In the absence of infection, RBC production balances110
natural death (which occurs at a rate, µ), so K = λR
∗
λ−µR∗ , where R
∗ represents the RBC density111
at homeostatic equilibrium. The final term represents a mass action infection process, and p is112
the rate at which merozoites invade RBCs upon contact.113
The dynamics of infected RBCs are given by114
dI
dt
= pR(t)M(t) − µI − pR (t− α)M (t− α)S. (2)
where S indicates the proportion of infected red blood cells surviving development, equal to115
e−µα when t > α and in the absence of drugs. An infected cell is generated when a merozoite116
invades an uninfected RBC and can be lost via two different routes. First, infected RBCs can117
die at a background rate µ. Second, infected RBCs burst to release merozoites after a period118
of α days (i.e., one day for the rodent malaria parasite, P. chabaudi). For simplicity, we omit119
immune responses that remove infected RBCs, though simulations of this model including a120
saturating immune response have delivered similar optimal conversion rate profiles (results not121
shown).122
The dynamics of merozoites and gametocytes are described as123
dM
dt
= (1 − c(t))βpR (t− α)M (t− α)S − pR(t)M(t) − µMM(t) (3)
dG
dt
= c(t)pR (t− α)M (t− α)S − µGG(t) (4)
where c(t) is the proportion of parasites in a given cohort of infected RBCs that become124
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gametocytes after successful development (i.e., the conversion rate). We allow the conversion125
rate to vary over the course of infection, as has been observed in experimental data (Greischar126
et al. 2016b; Pollitt et al. 2011; Reece et al. 2005). The burst size, β, is the number of merozoites127
released from each infected RBC surviving the developmental period. Merozoites die at a rate128
µM and gametocytes die at a rate µG.129









= (1 − c(t))β I0S
α







S = e−µt (8)
for t ≤ α.132
2.2 Drug Action133
We incorporate the model of drug action presented in Huijben et al. (2013), which was parameterised134
to describe the consequences of pyrimethamine for Plasmodium chabaudi parasites (Landau135
1965) in infections of female C57BL6 mice (Schneider et al. 2012). According to this model,136
as long as the drug is present at a sufficiently high concentration in the host, it kills a fixed137
proportion (94%) of parasites each day. The underlying within-host model assumed in Huijben138
et al. (2013) was in discrete-time and cohorts of infected cells burst synchronously. To approximate139
this drug action in our model, we apply an additional death rate, µd, to infected cells. By setting140
µd = −ln(1− 0.94) = 2.81 we ensure that ∼94% of infected cells die within the one day parasite141
developmental cycle. Different drug doses, d, modify the length of drug action, l, beyond the142
7
days the drug was administered (see Figure A.1 in Appendix A, for how l varies with dose):143
l = 3.557 − 2.586
1 + e−8.821+d
. (9)
Therefore, parasites are subject to a drug-induced mortality rate for each day that the drugs144
are administered, plus an additional l days afterwards. To explore the consequences of different145
strengths of drug treatment on optimal patterns of conversion rates, we simulate several treatment146
regimes: drug doses of 0-15 mg/kg, each administered for two consecutive days (days 11 and147
12 post-infection). Determining the survival of infected RBCs (S) requires integrating these148





























, l + 12 ≤ t < l + 12 + α,
exp(−µα), otherwise.
(10)
Given our other model parameters, these treatment regimes encompass outcomes from a small,151
transient reductions in parasite loads, to a strong reduction in parasite load that would prevent152
further transmission on the timescale of our simulation. A schematic of the model of drug action153
is presented in Figure A.2 in Appendix A.154
2.3 Optimisation155
To find optimal patterns of transmission investment, we use the optim function in R version156
3.0.2 and define the cumulative transmission potential as our measure of fitness. This metric157
translates daily estimates of gametocyte density into the probability of that density resulting in158
an infected mosquito, assuming mosquitoes are abundant and biting hosts on a regular basis.159
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The relationship between gametocyte densities and transmission probability is assumed to be160
sigmoidal, as has been experimentally derived for P. chabaudi by Bell et al. (2012). Using their161





1 + e−12.69+3.6 log10G(t)
dt, (11)
where G(t) is the gametocyte density at time point t, and η is the day post-infection at which our163
simulated infection ends. A sigmoidal relationship between gametocyte density and transmission164
success has also been reported for P. falciparum (Huijben et al. 2010) and gives similar results165
if used instead of the fitness function described here (see Figure A.3 in Appendix A). Our166
model describes early infection dynamics, before major adaptive immune responses develop.167
We therefore simulate a 20 day infection over which we calculate the cumulative transmission168
probability, as has been done previously (Greischar et al. 2016a).169
In a first set of optimisations, we define transmission investment to be a constant (c(t) = x,170
for all t) and determine the optimal time-invariant conversion rate. Second, following Greischar171
et al. (2016a), we use cubic splines for the optimisation of time-varying conversion strategies,172
implemented in R with the splines package. Cubic splines require only four parameters to173
specify but allow considerable flexibility in the pattern of conversion over a 20-day infection,174
and more complicated splines yield minimal fitness gains (Greischar et al. 2016a). Conversion175
rates must be constrained to vary between zero and one, so we take the complimentary log-log of176
the value specified by the spline, that is c(t) = exp(− exp(spline value at time t)). The starting177
values of the variables and the assumed value for each of the model parameters are given in Table178
1, and each optimisation is initiated by setting all spline parameters to an arbitrary starting guess179
of 0.5. Although no numerical optimisation routine can guarantee finding a globally optimal180
solution, we sought to substantiate our findings by testing, for a given environment (i.e., drug181
dose), whether the putative optimal strategy for that environment out-performed the putative182
optimal strategies from other environments.183
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3 Results184
3.1 Constant conversion rates185
Following previous work (Greischar et al. 2016a), we first constrained conversion rate in our186
within-host model to be a constant, and determined which single rate, maintained throughout187
the whole infection, produced the highest estimate of our parasite fitness proxy (i.e., cumulative188
transmission potential). In the absence of drugs, we find a similar optimal level of transmission189
investment as predicted previously (Greischar et al. 2016a). Drug treatment reduces the optimal190
level of transmission investment, with the lowest conversion rate predicted for the highest drug191
dose simulated (Figure 1A). We found little variation in the optimal transmission investment192
over low and moderate drug doses, as would be expected given our assumption that the drug193
dose changes the number of days of drug action rather than the killing rate (Huijben et al.194
2013). For doses below 6 mg/kg, this formulation predicts little difference in the duration of195
drug action (see Figure A.1 in appendix A) or consequences for parasite fitness, as can be seen196
in Figure 1B. We therefore focus on 5 mg/kg, 8 mg/kg and 15 mg/kg as representative low,197
medium, and high drug doses, respectively, for the remainder of our analyses. The step-wise198
decrease in predicted conversion rates observed from a dose of 0 to 2 mg/kg and from a dose199
of 8 to 10 mg/kg closely follows the fitness effects that these increasing doses would have on200
parasites employing a non-drug adapted conversion rate (Figure 1B, grey bars). Interestingly,201
we do not see a similar decrease in the predicted optimal conversion rate when the drug dose202
increases from 6 to 8 mg/kg, despite a substantial decrease in expected fitness for a non-drug203
adapted strategy. An explanation for this may be found in the fact that a constant conversion204
rate represents a compromise, balancing the need to sustain a high enough asexual source205
population for conversion in the face of drug killing and having a sufficiently high conversion206
rate to successfully translate that asexual source population into onward transmission. Up to207
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a dose of 8 mg/kg, slight increases in conversion rates can counteract lost fitness due to slight208
reductions in the asexual source population from higher doses. With a dose of 10 mg/kg or209
more, the asexual source population and gametocytes are reduced to such an extent that no210
more transmission is possible after the action of drugs. Therefore, the best option for a parasite211
is to restrain and increase the asexual source population that will be converted before the end212
of drug action.213
We assume that all parasites within an infection are genetically identical; consequently, our214
fitness proxy is the cumulative probability of transmission over the course of infection. Since215
our simulated infections run for 20 days, 20 represents the maximum cumulative transmission216
potential that would be achieved by a parasite genotype that sustained a sufficiently high217
gametocyte density to transmit to mosquitoes with 100% efficacy every day. Even in the absence218
of drugs, parasites cannot achieve 100% transmission efficacy at every point in the simulation,219
especially at the beginning of the infection when parasite numbers are low; hence, the maximum220
cumulative transmission potential is approximately 11 for the optimal level of fixed transmission221
investment of 0.42 in the absence of drugs (Figure 1B). The grey bars demonstrate the fitness222
achieved by parasites employing this same conversion rate (0.42) in the face of drug treatment.223
As expected, parasite fitness is lost as drug treatment reduces numbers. Some fitness can be224
recouped by adopting lower conversion rates (the drug dose-specific optima, black bars). Indeed,225
with low drug doses, reduced conversion rates allow parasites to maintain roughly 90% of the226
fitness achieved in the absence of drugs.227
3.2 Time-varying conversion rates228
Next, we allowed the conversion rate to vary over the course of the infection and determined229
what pattern of transmission investment would maximize cumulative transmission potential230
(Eqn. 11). The work of Greischar et al. (2016a) suggests that, in the absence of drug treatment,231
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optimal patterns of conversion rate comprise roughly four distinguishable phases: (1) an “initial232
replication” phase where parasites delay gametocyte production to increase their numbers; (2)233
a “peak conversion” phase where parasites dramatically increase transmission investment to234
capitalize on their large numbers; (3) a “trough” where parasites reduce transmission investment235
to compensate for declining numbers in the face of resource limitation; and finally, (4) “terminal236
investment”, where parasites invest heavily into gametocyte production before the infection ends.237
We find qualitatively similar strategies (with the same four phases) in drug treated infections238
(Figure 2). The corresponding dynamics of infected red blood cells and gametocytes are shown239
in Figure 3. A key difference in the predicted optimal patterns of conversion in drug treated240
compared to untreated infections is an earlier and faster reduction in conversion rates (i.e.,241
greater reproductive restraint) following the initial peak conversion (compare black to coloured242
lines in Figure 2). Comparing low and medium dose treatment regimes, we find that increasing243
dose is accompanied by greater reproductive restraint following treatment. The best response to244
a high drug dose is early terminal investment, which ultimately ends the infection (see infection245
dynamics in Figure 3C).246
To identify the fitness consequences of these different strategies, we plot cumulative transmission247
potential over the course of infections. In Appendix A, we confirm that the putative optimal248
strategy against a given dose outperforms the putative optimal strategies from other doses249
(see Figure A.4). The optimal strategies—and the corresponding cumulative transmission250
potential—are similar prior to drug treatment (Figures 2, and 4, respectively). After drug251
treatment, the transmission investment strategies diverge, and there are clear costs to parasites252
that employ the incorrect strategy for the drug dose they encounter within the host (compare253
coloured to dashed grey curves in Figure 4). Specifically, in the absence of drug treatment, the254
optimal drug-free strategy accrues fitness at nearly the maximal rate, corresponding to almost255
100% chance of transmitting to mosquitoes each day (black lines, Figure 4). But, this strategy256
performs successively worse in the face of increasing drug doses (dashed grey lines Figure 4; see257
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also Figure 3 for corresponding infection dynamics). The optimal strategies for low, medium, and258
high drug doses allow parasites to recoup a substantial portion of these fitness losses (coloured259
lines in Figure 4), attributable to greater reproductive restraint immediately after drug treatment260
(Figure 2). Notice that in the face of a high drug dose, the drug-free strategy accrues no fitness261
following treatment (Figure 4C, dashed grey line), despite the fact that gametocytes are still262
circulating for days in those infections (Figure 3C, dashed grey line). This is because the densities263
are too low to achieve more than a negligible probability of transmission. In untreated infections,264
parasites that use reproductive restraint pay only a small fitness cost whereas parasites employing265
strategies against high drug doses, pay a more substantial fitness cost due to premature terminal266
investment (Figure 5A).267
While reproductive restraint in response to treatment can, to some extent, buffer against the268
effects of drugs, our models predict that treatment still leads to reductions in parasite fitness and,269
importantly, reductions in transmission potential. Since reproductive restraint necessarily means270
prioritization of asexual replication and it is these parasite stages that are most responsible for271
the virulence (harm) of a malaria infection, there may be consequences of shifting patterns of272
conversion at the host (or clinical) level. Drug treatment reduces infected RBC densities, even273
if parasites alter their conversion rates (Figure 3), but what if parasites employ drug-adapted274
strategies in an infection that remains untreated? Figure 5B shows that, in an untreated host,275
infections composed of parasites using a drug-adapted strategy (coloured lines) are predicted to276
result in much more rapid declines in uninfected RBC densities, and greater anemia as measured277
by minimum RBC counts, compared to parasites using the best strategy in the absence of drugs278
(black line).279
Of course, the likelihood of a drug-adapted strategy becoming fixed in the parasite population280
depends on the frequency that parasites encounter drug-treated hosts, the benefits of altered281
patterns of conversion in a drug-treated host, as well as the costs of that strategy in an untreated282
13
host. Using the fitness estimates for the different strategies in different environments (Table B.1283
in Appendix B), we calculate the expected fitness for the drug-adapted and non-drug adapted284
strategies in a host population where some proportion of hosts are treated (Figure B.1). If b285
is the increase in fitness achieved by the drug-adapted strain in the presence of drugs (i.e., the286
benefit), c is the reduced fitness of the drug-adapted strain in an untreated host (i.e., the cost),287
and f is the proportion of infected hosts that are drug-treated, then it is trivial to show (see288






Put another way, the drug-adapted strategy will be favoured when the ratio of the benefits to291







Given our estimated fitnesses for the different strategies in different host environments, the293
drug-adapted strategy will be favoured over the non-drug adapted strategy when at least ∼ 40%294
of infections are treated with a low or medium dose, or at least 86% of infections receive a high295
dose treatment. The early terminal investment strategy predicted to be optimal in the face of296
a high drug dose gains only a small fitness advantage in a treated host, while it suffers a large297
fitness cost in an untreated host (see also Table B.1), explaining why drug treatment would have298
to be very common to generate a sufficient selection pressure to favour that strategy.299
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4 Discussion300
The evolution of drug resistant parasites is a serious obstacle to the control of malaria (Dondorp301
et al. 2009; White 2004). In addition to classical resistance mechanisms, we have shown that302
drug treatment can select for altered life history of malaria parasites and, specifically, changing303
patterns of allocation to transmission versus asexual parasite stages. Our work predicts that304
reproductive restraint is adaptive in drug treated infections, allowing parasites to compensate for305
the reductions in asexual densities caused by the drug. We also show that parasite adaptation306
to drug treatment could lead to worse outcomes for hosts that remain untreated, although as307
would be expected this outcome depends on the frequency with which parasites find themselves308
in treated hosts as well as the precise costs and benefits associated with different investment309
patterns in different environments.310
Experimental evidence suggests that malaria parasites do alter their investment in transmission311
in response to drugs. Reece et al. (2010), for example, found a decrease in conversion in human312
malaria parasites exposed to low doses of drugs in vitro, as our model predicts, unless they313
were known to be “classically” drug-resistant parasites, which showed no change in investment314
(a result that highlights the multiple routes available for mitigating the effects of drugs). A315
similar study found no effect of drug dose on conversion rates (Peatey et al. 2009) and an in vivo316
rodent malaria experiment suggested that subcurative drug doses lead to increased conversion317
(Buckling et al. 1997). In contrast to the results of Reece et al. (2010), these latter two examples318
show parasite responses that appear maladaptive in light of our model results, raising at least319
two further questions. First, have parasite strategies been accurately measured? Inferring320
conversion rates is fraught with difficulties that have only recently been resolved (Greischar321
et al. 2016b), and reanalysis of past data sets could reconcile the discrepancy between theoretical322
predictions and empirical estimates of transmission investment. Second, are parasites capable323
of evolving adaptive transmission strategies to the novel selection pressure of drug treatment?324
15
Addressing this question means evaluating whether the parasites in these experiments would325
have achieved greater fitness than ones with different responses, which necessitates tools for326
manipulating parasite strategies. Advances in understanding the molecular pathways associated327
with commitment to gametocytogenesis (e.g., Brancucci et al. 2015) may bring such tools for328
experimental manipulation into reach.329
Recent work has focused on dormancy as another non-classical resistance mechanism thought330
to be employed by malaria parasites (e.g., Codd et al. 2011; Hott et al. 2015; Paloque et al.331
2016; Teuscher et al. 2010). This delayed development confers protection against the effects332
of fast-acting drugs that decay rapidly within a host, but whether such a strategy would be333
beneficial against drugs with longer half-lives is unclear. Parasites can stall their intra-erythrocytic334
development for many days, but only a small fraction—less than two percent—appear to successfully335
recover and resume development even at low drug doses (Teuscher et al. 2010). It is not336
clear that such a low percentage of parasites entering dormancy can explain malaria dynamics337
in patients (Saralamba et al. 2011). Further, the fitness consequences of dormancy are not338
intuitive: surviving the effects of drugs is clearly good from the parasite’s perspective, but339
stalling development means stalling production of transmission stages and missing out on any340
transmission opportunities during the dormant phase. In contrast, parasites can recover substantially341
more than two percent of their numbers by modifying transmission investment under some342
treatment regimes. Indeed, Figure 3 suggests that parasite densities can actually increase by an343
order of magnitude or more within less than 4 days and this modified life history translates to344
fitness gains (Figure 4). It is interesting to consider how these two mechanisms of non-classical345
resistance would affect host health. At least in the short term, dormancy should reduce pathology346
associated with parasite replication as well as immunopathology, while reduced investment in347
transmission is likely to do the opposite.348
We have shown that, in principle, altered life history can protect against the effects of349
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drugs and while we have used a model of drug action that was parameterized for a particular350
drug (pyrimethamine; Huijben et al. 2013), the phenomenological description we employ should351
capture the effects of many different drugs. Though there will be differences among individual352
hosts in drug metabolism that would affect, for example, the duration of drug action, our353
exploration of a range of drug doses should capture much of this variation. One exception to354
this generality is drugs that directly target gametocytes (e.g., primaquine, White et al. 2014a).355
The relative susceptibility of asexuals and gametocytes to the drug will alter the costs and356
benefits of producing each stage, so different drugs may be expected to have different effects on357
optimal patterns of transmission investment. For example, a drug with a strong gametocidal358
effect may generate an advantage to reproductive restraint when drugs are present but promote359
the production of surplus gametocytes to compensate for those killed by drugs when drugs have360
cleared or may promote earlier production of gametocytes to compensate for lost transmission361
opportunities during drug treatment. Predicting evolutionary trajectories in response to such362
drugs will require precise calibration of the relative susceptibility of different parasite stages.363
Further, we have ignored within-host competition and thus evolution operating at the364
within-host scale, but where malaria is endemic, multi-genotype infections are the rule rather365
than the exception (e.g. Baruah et al. 2009; Juliano et al. 2010). Previous theoretical and366
experimental work shows that competition favours reproductive restraint (Greischar et al. 2016a,c;367
McKenzie and Bossert 1998; Mideo and Day 2008; Pollitt et al. 2011), so it is possible that368
our prediction of that same response in the face of drug treatment would remain unchanged.369
However, just as there is genetic variation for competitive ability (Bell et al. 2006; de Roode370
et al. 2005a,b), there may be genetic variation in sensitivity to drugs (and in P. falciparum371
there appears to be; e.g., Mideo et al. (2016)). If variation in drug sensitivity is unrelated372
to transmission investment, then it would alter the costs and benefits to different parasite373
genotypes of altering that investment. Modelling the dynamic consequences of competition and374
the interplay between different sources of resistance on the evolution of parasite life history would375
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be an interesting route for future investigation. Importantly, there may also be genetic variation376
in the shape of the relationship between within-host gametocyte densities and the probability377
of transmission to mosquitos. As far as we are aware, this relationship has been quantified378
only a few times and only for a few distinct strains (Bell et al. 2012; Huijben et al. 2010; Paul379
et al. 2007). While the qualitative shapes of these relationships remain the same, there are380
quantitative differences in their parametrization. We found that these differences did not alter381
our predictions (see figure A.3 in supplementary material), but further empirical exploration of382
this relationship is warranted, as is theoretical investigation of how any quantitative changes in383
this relationship alter evolutionary predictions.384
While our model allows for variation across infections treated with different drug regimes385
and variation over time within infections, our heuristic analysis also constrains variation at both386
of these scales. First, to determine when evolution should favour a drug-adapted strategy, we387
assumed that there were only two strategies available to parasites: the pattern of transmission388
investment predicted to be best in an untreated host or the one predicted to be best in the389
presence of a particular drug dose. In a heterogeneous host population, some intermediate390
parasite investment strategy may perform better than either of these two “extremes”. Second,391
our model does not allow for parasites to directly receive and respond to cues within infections,392
i.e., it is not a model of plasticity. Put another way, the model implicitly assumes that parasites393
have perfect knowledge about the timing of drug treatment (which does not vary across treated394
hosts) and optimal patterns of investment may allow parasites to, in effect, prepare in advance395
for drug treatment. This scenario may not be too far from reality in some areas. Drug doses are396
standardised by WHO guidelines (WHO 2015b) and hosts likely seek treatment when symptoms397
appear, which generally correlates with peak parasite density (Kachur et al. 2006), though there398
will be variation across individual hosts in the timing of early dynamics. How much fitness399
could be gained by allowing parasites in our model to detect and respond to drug treatment more400
directly is unclear, since our results suggest that differences in investment early in infections (and,401
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in particular, before drug treatment) have little effect on parasite fitness. Consistent with this,402
Greischar et al. (2016a) found that investing little in transmission at the beginning of infections403
is adaptive in untreated hosts, regardless of other changes to the within-host environment. Thus,404
it seems unlikely that allowing parasites more flexibility in pre-treatment patterns of investment405
would result in different life history strategies than we have predicted. On the other hand,406
if parasites could respond plastically to the presence of drugs in the within-host environment407
(instead of through evolutionary change, as we have focused on), then this would avoid the408
negative consequences for host health we report.409
The evolution of classical resistance is the expected result of using chemical interventions410
to kill parasites (or, in evolutionary terms, reduce their fitness), but, as we have shown, failing411
to consider the potential for non-classical resistance, like life history evolution, can yield overly412
optimistic predictions about the epidemiological or clinical effects of those interventions. Similarly,413
Lynch et al. (2008) used models to investigate the influence of different anti-helminth interventions414
on nematode life history, finding that disease control programs may frequently select for increasingly415
fecund worms, with ramifications for clinical outcomes and onward transmission. In an experimental416
system, filarial nematodes altered their reproductive schedules in the presence of specialized417
immune cells, producing transmissible stages faster and in greater numbers (Babayan et al.418
2010). Since these are the same immune cells on which current experimental vaccines rely, this419
work suggests that nematodes could reduce the benefits of vaccination through plasticity in life420
history. Further, the mosquitoes that transmit malaria and other diseases can also respond421
to intervention efforts with non-classical resistance, including, for example, changes in feeding422
behaviour or timing to avoid insecticide-treated bednets (Gatton et al. 2013; Sokhna et al. 2013).423
An important question is how treatment recommendations would change in light of our424
predictions about optimal malaria parasite life histories. Regardless of the life history shifts we425
predict here, parasites fitness and within-host densities are reduced by drug treatment. This426
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suggests that despite the evolution of non-classical resistance, drug treatment offers epidemiological427
and clinical benefits. Those benefits are not as great as they would be in the absence of life428
history evolution and, importantly, any hosts that remained untreated could be worse off if429
drug-adapted strategies became fixed in the parasite population. Further, as a result of altered430
patterns of transmission investment, parasites could maintain higher within-host densities in the431
face of drug treatment, potentially facilitating the evolution of classical resistance. The theory432
developed here provides a basis for assessing the constraints and limits on parasite life history433
evolution in response to human interventions.434
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Figure 1. Lower conversion rates can buffer the effects of drugs. (A) Optimal constant
conversion rates in the face of drug treatment (labeled as doses in mg/kg) are lower
than in the absence of drugs. (B) As expected, drug treatment reduces parasite fitness
(i.e., cumulative transmission potential). Grey bars indicate fitness when parasites are
constrained to the drug-free optimal conversion rate (∼0.42). Black bars show the fitness
gains achieved by adopting the dose-specific optimal conversion rate (from A). With lower





























Figure 2. The optimal pattern of conversion over the course of infections. The black line
shows the predicted best response in an untreated infection. When infections are treated
(coloured lines), regardless of dose, parasites do better by reducing conversion (purple:
low dose, 5 mg/kg; blue: medium dose, 8 mg/kg; red: high dose, 15 mg/kg). Drugs are
administered on the days denoted by the grey bar.If drug treatment reduces the infection
to a degree where parasites cannot expect any future transmission, then the best response
for parasites is to terminally invest (as suggested by the red line). Note that the patterns
diverge before drug treatment due to the constraints of our fitting regime; however, early


























































































































































Figure 3. The within-host dynamics of infected red blood cells (i.e., asexual parasites;
top row) and gametocytes (bottom row). Coloured lines show dynamics when parasites
are using the optimal conversion profiles for a given drug treatment (A: low dose, purple;
B: medium dose, blue; C: high dose, red). The black lines show dynamics in the absence
of treatment, for parasites using the optimal drug-free pattern of conversion, while the
dashed grey lines show how the different drug treatment regimes impact these dynamics
if parasite life history patterns are unchanged from the drug-free optimum. Grey bars
denote the days of drug treatment and the horizontal lines in the bottom row indicate the
gametocyte density at which there is a 10% probability of transmitting to a mosquito,
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(C)
Day post−infection
Figure 4. Cumulative transmission potential (fitness) over the course of infections. Given
our fitness function, a parasite can maximally transmit with a probability of 1 each day,
reaching a cumulative transmission potential of 20 at the end of the simulated infection.
Black lines show the fitness obtained by a parasite adopting the drug-free optimal pattern
of conversion over the course of an untreated infection. Dashed grey lines show the
consequences of drug treatment on parasites using that same strategy in the face of drug
treatment: (A) low dose, 5 mg/kg; (B) medium dose, 8 mg/kg; (C) high dose, 15 mg/kg.
Coloured lines show the fitness obtained by parasites using the drug-dose specific optimal
patterns of conversion (from Figure 2) in the face of drug treatment and indicate that
parasites can recover some of the fitness lost due to drug treatment by altering patterns




















































Figure 5. Consequences of parasite adaptation to drug-treated infections. (A)
The cumulative transmission potential in untreated infections where parasites employ
different conversion rate strategies. Reproductive restraint in untreated infections
produces only small transmission costs (purple and blue line) compared to strategies for
untreated infections (black line) whereas terminating an infection early has bigger fitness
consequences (red line). (B) The dynamics of uninfected red blood cells in those infections.
Simulations assume optimal strategies for untreated infections (black), infections treated
with a low dose (purple), medium dose (blue), and high dose (red). The reproductive
restraint predicted for drug-adapted strategies leads to earlier declines in RBCs and lower
minimum values (i.e., greater anemia) when infections are not drug treated.
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Table 1. Model parameters.
Parameter Description Value or range Reference
R∗ red blood cell density of
a healthy mouse
8.5x106 cells/µL Savill et al. (2009)
λ maximal red blood cell
production rate
3.7x105 RBCs/µL Savill et al. (2009)
µ red blood cell death rate 0.025/day Miller et al. (2010)
p maximal per merozoite
invasion rate
4x10−6/day Mideo et al. (2008)
α bursting delay 1 day Landau and Boulard
(1978)
β burst size 10 merozoites Mideo et al. (2008)
µM merozoite death rate 48/day Mideo et al. (2008)
µG gametocyte death rate 4/day Gautret et al. (1996)
µd drug-induced death rate
of infected cells
2.81/day adapted from Huijben
et al. (2013)
I0 initial dose of infected
red blood cells
43.85965/µL ∼ 104 per mouse
d drug dose 1-10 mg/kg Huijben et al. (2013)
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Appendix A Supplementary Figures
Huijben et al. (2013) parameterised a model for the action of pyrimethamine against Plasmodium
chabaudi in mice, finding that the dose of drugs affected the duration of drug action. We show
this relationship (i.e., solutions to Equation 9 of the main text) in Figure A.1. A schematic of
the full drug action model is presented in Figure A.2. In Figure A.3, we explore the effects of
using a different fitness function on the predicted optimal patterns of investment in the absence
of drug treatment and with a medium dose drug treatment. Finally, Figure A.4 shows the
fitnesses achieved by different strategies in different environments (i.e., untreated or treated
hosts). In each case, the optimal strategy predicted for a given environment outperforms the
predicted optimal strategies for other environments.








































Figure A.1. Drug dose affects duration of drug-related parasite killing, but not the rate at
which parasites are killed. Shown are the additional days of drug action, beyond the days when
drugs are administered, when drugs are predicted to still be “active” (as defined in Huijben
























Figure A.2. Schematic of drug action in our model, a stylized version of how pyrimethamine
acts against P.chabaudi. In this example, drug treatment is composed of two doses of 9 mg/kg,
administered on day 11 and 12. The last dose determines how long the drugs will persist in
the host after treatment, here an additional ∼2.4 days of drug action. Before and after drug






















































Figure A.3. The optimal pattern of conversion over the course of infections, using equation “q2”
in Huijben et al. (2010), rather than equation 11 of the main text to define fitness. (A) The
black line shows the predicted best response in an untreated infection for the q2 fitness equation
and the fitness equation proposed by Bell et al. (2012), used in this paper and marked “Bell”.(B)
When infections are treated with a moderate drug dose (blue line, 8 mg/kg), parasites do better
by reducing conversion, for both fitness functions. Drugs are administered on the days denoted
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(D)
Day post−infection
Figure A.4. The cumulative transmission potential of different drug-adapted strategies in
untreated hosts (A), hosts treated with 5 mg/kg of drugs (B), 8 mg/kg (C), and 15 mg/kg
(D). For each drug treatment, the putative optimal strategy against that dose outperforms the
putative optimal strategies from other doses. Grey bars denote the days of drug treatment.
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B Fitness Calculations
Imagine the following set of fitnesses for a non-drug adapted and a drug-adapted pattern of
transmission investment (first subscript 0 or D, respectively) of malaria parasites in untreated
and treated host (second subscript 0 or D, respectively)
w0,0 = a (B.1)
w0,D = a− d
wD,0 = a− c
wD,D = a− d + b
where d is the reduction in fitness of the non-drug adapted strain due to drug treatment (i.e.,
the drug effect), c is the reduced fitness of the drug-adapted strain in an untreated host (i.e.,
cost to “resistance”), and b is the increase in fitness achieved by the drug-adapted strain in the
presence of drugs (i.e., the benefit of “resistance”).
We can write the expected fitness of the two different strategies in a host population, where
a proportion, f , of hosts receive drug treatment:
E [w0] = fw0,D + (1 − f)w0,0 (B.2)
E [wD] = fwD,D + (1 − f)wD,0.
Substituting the fitness expressions from B.1 into B.2 and rearranging, we find that the





Put another way, the drug-adapted strategy will be favoured when the ratio of the benefits







In Table B.1 we list the cumulative transmission potential (as predicted by our model),
over a 20-day simulated infection, for each of the predicted drug-adapted strategies, in the
presence and absence of drug treatment, as well as the non-drug adapted strategy in each of
these environments. From these values we can plot the expected fitness of different strategies
(i.e., solutions to Equations B.2) over different values of f (Figure B.1). We see that over a
range of f values, the non-drug adapted strategies performs better on average than the drug
adapted strategy, for all drug doses, but above a given f value, the drug-adapted strategy will
be favoured. From the fitness values, we can also calculate b and c for each of the drug-adapted
strategies (Table B.2). Plugging these costs and benefits into equation B.3, gives rise to the
frequencies of drug treatment required to favour the drug-adapted over the non-drug adapted
strategies reported in the main text (i.e., the intersection of the lines in Figure B.1).
4
Table B.1. Estimated fitness values (i.e.,
cumulative transmission potential) for different
transmission investment strategies in different
host environments, as predicted by the model
presented in the main text.
Strategy Environment (drug dose)
0 5 8 15




Table B.2. Calculated benefits, b, and costs, c,
of drug-adapted strategies.





Figure B.1. Expected fitness for different transmission investment strategies in a host
population treated with a particular drug dose (A: low; B: medium; C: high) at a given
frequency. Lines show the weighted average of fitness achieved in untreated and treated
infections (i.e., solutions to Equations B.2). Black lines represent the transmission investment
strategy predicted to be best in the absence of drug treatment (the “non-drug adapted”
strategy); coloured lines represent the transmission investment strategy predicted to be best in
the face of a low drug dose (purple), medium drug dose (blue) or high drug dose (red).
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